How to Apply for an SPC in the United Kingdom (step‑by‑step, Post‑2025 Rules)

If you hold a patent covering a regulated pharmaceutical or agrochemical product in the United Kingdom, a Supplementary Protection Certificate (SPC) can extend your market exclusivity for up to five years beyond patent expiry. Understanding how to apply for an SPC in the United Kingdom has become more urgent since 1 January 2025, when the UK Intellectual Property Office (UKIPO) began requiring a UK marketing authorisation (UK MA) granted by the Medicines and Healthcare products Regulatory Agency (MHRA) as the primary basis for most new applications. This guide sets out the eligibility criteria, step‑by‑step filing procedure, required documents, deadlines, indicative costs and common pitfalls, all updated to reflect the post‑2025 landscape that life‑sciences teams are now navigating.

Overview of the SPC process and who it applies to

A Supplementary Protection Certificate is a national intellectual‑property right that takes effect immediately after the basic patent expires. It does not extend the patent term itself; instead, it confers protection equivalent to the patent but limited to the specific product covered by the marketing authorisation. The rationale is straightforward: developers of medicines and plant‑protection products often spend years securing regulatory approval, which erodes the effective patent life available for commercial exploitation. The SPC compensates for that lost time.

SPCs are available for human medicinal products, veterinary medicinal products and plant‑protection products. The two regulators involved in the UK process are the UKIPO, which examines and grants the certificate, and the MHRA, which issues the marketing authorisation that underpins the application. Only the proprietor of the basic patent, or a successor in title, may apply.

Eligibility and SPC UK requirements

Before assembling a filing pack, applicants must confirm that four cumulative conditions are met. Failure on any one of these will result in refusal.

Basic patent requirement

The applicant must hold a valid basic patent in force in the United Kingdom. This may be a UK national patent or a European patent (UK), commonly referred to as an EP(UK), that has been validated and is in force as a UK bundle patent. The applicant must be the registered proprietor or a successor in title under the Patents Act 1977. Where the patent has been assigned, applicants should ensure the assignment is recorded at the UKIPO before filing. Licensees who are not proprietors cannot file in their own name unless the patent has been formally transferred to them.

Marketing authorisation basis: the UK MA requirement

Since 1 January 2025, the marketing authorisation basis for a UK SPC must, in most cases, be a UK marketing authorisation granted by the MHRA. Centralised EU marketing authorisations are generally no longer acceptable as the basis for new UK SPC applications. This change, announced by the UK Government, reflects the UK’s post‑Brexit regulatory independence and has significant practical consequences for life‑sciences companies whose products were historically authorised through EU centralised procedures.

The relevant authorisation must be the first authorisation to place the product on the market in the United Kingdom. Where multiple UK MAs exist (for example, covering different indications or formulations of the same active ingredient), the earliest relevant UK MA is typically the one that should be cited. Applicants can verify MA details through the MHRA products database.

Claim coverage mapping: small molecules, biologics and diagnostics

The product identified in the marketing authorisation must be “protected by” the claims of the basic patent. For a small‑molecule active ingredient named explicitly in a patent claim, mapping is usually straightforward, the claim names the compound and the MA covers it.

For biologics such as monoclonal antibodies, fusion proteins or vaccines, the analysis is more nuanced. Patent claims may define the product by amino‑acid sequence, by functional characteristics, or by a combination of structural and functional limitations. Applicants should prepare a detailed claim‑mapping memo that demonstrates how the authorised product falls within the scope of the patent claims. Industry observers expect UKIPO examiners to scrutinise biologic claim mapping more closely, particularly where claims use broad functional language. Engaging both patent and regulatory specialists at this stage reduces the risk of objections during examination.

How to apply for an SPC in the United Kingdom: step‑by‑step procedure

The SPC application timeline typically runs from initial claim‑to‑MA mapping through to grant and registration. The procedure below reflects UKIPO practice as outlined in official guidance.

Step 1: Conduct pre‑filing clearance and claim‑to‑MA mapping

Who: Patent attorney and regulatory scientist, working together.

1. Identify the relevant UK MA date(s) by searching the MHRA products database and confirm the product definition in the authorisation (active ingredient, salts, esters, combinations).
2. Map the patent claims to the authorised product. Produce a written claim‑mapping memo that cross‑references each relevant claim against the product as defined in the MA.
3. Confirm the identity of the applicant, verify that the patent proprietor recorded at the UKIPO is the intended applicant. If any assignment has occurred, ensure the chain of title is documented and registered.
4. Determine whether a paediatric extension may be sought and, if so, confirm that a compliant Paediatric Investigation Plan (PIP) is in place.

Output: Claim‑mapping memo, annotated patent claims, applicant confirmation and preliminary filing decision.

Step 2: Assemble the evidence pack and documents

Who: Regulatory affairs team and patent attorney.

1. Obtain a certified copy of the basic patent (UK patent grant certificate or EP(UK) grant extract from the EPO).
2. Obtain official evidence of the UK marketing authorisation, a certified copy or official extract from the MHRA, including the MA number and date of grant.
3. Complete the UKIPO SPC application form.
4. Prepare a signed Power of Attorney if an agent is filing on behalf of the proprietor.
5. Compile any assignment deeds or certified register extracts evidencing the chain of title.
6. Arrange certified English translations where any supporting document is not in English.

Output: A complete, ready‑to‑file evidence pack. See the documents needed for SPC table below for the full checklist.

Step 3: File the SPC application at the UKIPO

Who: Patent attorney or authorised representative.

1. Submit the completed application form together with all supporting documents via the prescribed UKIPO filing route.
2. Pay the applicable UKIPO filing fee.
3. Include the UK MA number and grant date as the marketing authorisation basis. After 1 January 2025, if multiple authorisations exist, include the one that provides the earliest relevant date.
4. Retain the stamped receipt or electronic filing confirmation and note the UKIPO file reference number.

Output: Filed application, UKIPO acknowledgement and file reference.

Step 4: Respond to UKIPO examination and any objections

Who: UKIPO examiner (raises queries); applicant or patent attorney (responds).

1. The UKIPO examines the application for compliance with eligibility criteria, including claim coverage, MA validity and filing deadline adherence.
2. If the examiner raises objections, for example, questioning whether the product is protected by the patent claims or whether the correct MA has been cited, respond within the timeframe specified in the examiner’s notice.
3. Provide any additional evidence requested (e.g., further MA documentation, updated assignment records or supplementary claim‑mapping analysis).

Output: Grant decision or, in some cases, refusal. If granted, the UKIPO proceeds to registration.

Step 5: SPC term calculation and entry into the register

Who: UKIPO and patent attorney.

1. Calculate the SPC term. The basic formula is: the period between the date of filing of the patent application and the date of the first UK marketing authorisation, minus five years. The maximum term is five years.
2. If a paediatric extension applies, an additional period of up to six months may be added.
3. The UKIPO issues the SPC certificate and registers it. Docket all renewal and maintenance payment dates immediately upon grant.

Output: SPC certificate, registered term dates and docketed renewal schedule.

SPC application timeline summary

Documents needed for an SPC application

The table below lists every document typically required when filing an SPC in the United Kingdom. Each item should be assembled during Step 2 of the procedure above. Documents flagged with an asterisk are newly emphasised under the post‑2025 rules.

Quick pre‑filing checklist:

• All certified copies obtained and clearly labelled with patent/MA numbers.
• Power of Attorney signed, dated and matching the recorded proprietor.
• Assignment chain complete, no gaps between original patentee and current applicant.
• Cover memo prepared summarising the application and cross‑referencing each enclosed document.
• Fee payment arranged before or on filing date.

SPC filing deadline UK: timeline and key deadlines

Missing the statutory filing window is the single most common reason SPC applications fail. The rules are strict and there is generally no mechanism to extend the deadline.

The six‑month rule

An SPC application must be filed within the later of:

• Six months from the date on which the first authorisation to place the product on the market was granted in the United Kingdom, or
• Six months from the date of grant of the basic patent.

The operative word is “later”, whichever of these two dates falls second determines the deadline.

Worked example

A patent is granted on 1 March 2024. The first UK marketing authorisation for the product is granted by the MHRA on 15 October 2024. The two six‑month windows expire on 1 September 2024 (patent) and 15 April 2025 (UK MA). The later date is 15 April 2025, so the applicant must file on or before that date.

Maximum SPC term and paediatric extension

The maximum duration of an SPC is five years from the expiry of the basic patent. The term is calculated by reference to the period between the date of filing of the patent application and the date of the first marketing authorisation, minus five years, but it cannot exceed five years.

A paediatric extension of up to six additional months may be available where the patent proprietor has complied with an agreed Paediatric Investigation Plan (PIP). The paediatric extension is a separate application or notification process and requires submission of a PIP compliance certificate.

Key deadlines at a glance

SPC cost UK: fees and tax considerations

The total cost of obtaining an SPC in the United Kingdom comprises official fees payable to the UKIPO, professional fees for patent attorney and regulatory support, and ancillary costs. The table below provides indicative ranges. Official UKIPO fee amounts should be verified against the current UKIPO fee schedule before filing, as rates are updated periodically.

SPCs are intellectual‑property rights. Royalty income or licensing revenue derived from an SPC is taxable under standard UK corporate tax rules. VAT will generally apply to professional fees charged by UK patent attorneys. Applicants should consult their tax advisors for portfolio‑specific guidance.

SPC 2025 changes and practical effects in 2026

On 1 January 2025, the UK Government implemented a significant change to the SPC regime: new UK SPC applications must, in most cases, rely on a UK marketing authorisation granted by the MHRA. Centralised EU marketing authorisations, which were previously accepted as the basis for UK SPCs, are generally no longer sufficient for new applications.

The practical effects of this change have been substantial throughout 2025 and into 2026. Life‑sciences companies have re‑mapped existing patent portfolios to identify products where a UK MA had not previously been obtained (because a centralised EU MA covered both EU and UK markets pre‑Brexit). Industry observers expect that many applicants have either applied for standalone UK MAs from the MHRA or adjusted their SPC filing timelines to align with anticipated MHRA authorisation dates.

For products where a centralised EU MA was granted before 1 January 2025, transitional provisions may apply. The GOV.UK guidance on these changes sets out the specific circumstances under which earlier authorisations may still be relevant. Applicants with legacy portfolios that predate the 2025 rule should review the official guidance on a case‑by‑case basis and seek specialist advice where the position is unclear.

Common pitfalls and how to avoid them

• Missing the six‑month filing window. This is the most frequent cause of lost SPC rights. Docket both the MA grant date and the patent grant date as soon as each is confirmed, and set internal alerts well before the six‑month deadline.
• Citing an EU Centralised MA instead of a UK MA. After 1 January 2025, most new applications require an MHRA‑granted UK marketing authorisation. Verify the MA basis early in the process to avoid a fatal objection.
• Inadequate claim‑to‑MA mapping for biologics. Broad or functionally defined patent claims require detailed mapping analysis. Involve both patent and regulatory specialists from Step 1, do not leave this to the filing stage.
• Incomplete chain of title. If the patent has been assigned, every link in the chain must be documented. Gaps or unregistered assignments at the filing date will trigger UKIPO objections and may be impossible to remedy within the deadline.
• Relying on uncertified document copies. The UKIPO expects certified copies of the patent grant and marketing authorisation. Uncertified photocopies or informal printouts may be rejected. Always order certified documents early enough to avoid last‑minute delays.

If a deadline has been missed: options are extremely limited. Extension mechanisms are rare and generally not available for the statutory six‑month filing period. Consult experienced counsel immediately to assess whether any residual strategies exist, including filings in other jurisdictions or restructuring through licensing arrangements.

Sources

1. GOV.UK, Supplementary Protection Certificates
2. GOV.UK, Changes to supplementary protection certificates on 1 January 2025
3. MHRA, Products database (marketing authorisations)
4. Manual of Patent Practice (UKIPO)
5. Patents Act 1977 (legislation.gov.uk)
6. Human Medicines Regulations 2012 (legislation.gov.uk)